We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.24B
AUM Growth
+$171M
Cap. Flow
+$215M
Cap. Flow %
2.98%
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$49.6M
2
EXAS
Exact Sciences
EXAS
+$26.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.9M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$24.6M
5
MTEM
Molecular Templates, Inc.
MTEM
+$18.3M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$35.1M
2
PACB icon
Pacific Biosciences
PACB
+$25.7M
3
EVH icon
Evolent Health
EVH
+$20.6M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$15.9M
5
MDT icon
Medtronic
MDT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 0.6%
3 Technology 0.53%
4 Communication Services 0.41%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RMD icon
101
ResMed
RMD
$28.4B
$13.3M 0.18%
77,805
– –
ONEM
102
DELISTED
1Life Healthcare
ONEM
$13.3M 0.18%
468,564
+21,757
+5% +$687K
ONC
103
BeOne Medicines Ltd
ONC
$32.5B
$11.3M 0.16%
39,400
-18,600
-32% -$4.37M
AMWL icon
104
American Well
AMWL
$211M
$11.3M 0.16%
+18,993
New +$10M
REGN icon
105
Regeneron Pharmaceuticals
REGN
$70.8B
$11.2M 0.15%
20,000
-3,100
-13% -$1.88M
CVS icon
106
CVS Health
CVS
$138B
$10.9M 0.15%
186,981
-44,700
-19% -$2.78M
LH icon
107
Labcorp
LH
$23.1B
$10.2M 0.14%
63,128
– –
TRHC
108
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$9.97M 0.14%
244,469
+27,888
+13% +$1.39M
OXFD
109
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$9.36M 0.13%
800,157
+116,362
+17% +$1.54M
SGEN
110
DELISTED
Seagen Inc. Common Stock
SGEN
$9.12M 0.13%
46,600
-8,300
-15% -$1.39M
COO icon
111
Cooper Companies
COO
$13.8B
$8.54M 0.12%
101,380
– –
GTHX
112
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$8.34M 0.12%
721,925
– –
CELL
113
DELISTED
PhenomeX Inc. Common Stock
CELL
$8.21M 0.11%
+107,510
New +$6.83M
ACCD
114
DELISTED
Accolade Inc
ACCD
$8.14M 0.11%
+209,327
New +$7.22M
CDTX
115
DELISTED
Cidara Therapeutics
CDTX
$8.04M 0.11%
141,125
– –
TMDX icon
116
Transmedics
TMDX
$2.51B
$7.95M 0.11%
577,147
+152,147
+36% +$2.61M
GILD icon
117
Gilead Sciences
GILD
$166B
$7.82M 0.11%
123,700
-10,800
-8% -$749K
XENT
118
DELISTED
Intersect ENT, Inc
XENT
$7.72M 0.11%
473,382
-89,708
-16% -$1.62M
XRAY icon
119
Dentsply Sirona
XRAY
$2.76B
$6.96M 0.1%
159,129
– –
AVTR icon
120
Avantor
AVTR
$7.31B
$6.91M 0.1%
307,089
-57,788
-16% -$1.2M
DGX icon
121
Quest Diagnostics
DGX
$23.2B
$6.87M 0.09%
60,005
– –
AKCA
122
DELISTED
Akcea Therapeutics Inc
AKCA
$6.17M 0.09%
340,264
-1,122,032
-77% -$15.9M
HZNP
123
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.01M 0.08%
77,400
-80,800
-51% -$5.56M
VCRA
124
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$5.86M 0.08%
201,390
-142,691
-41% -$3.86M
IART icon
125
Integra LifeSciences
IART
$1.49B
$5.78M 0.08%
122,426
-78,471
-39% -$3.73M
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2020 Portfolio in Review

As of Q3 2020, Bellevue Group held 226 positions worth $7.24B, up 2.4% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q3 2020 filing shows 18 new, 74 increased, 41 reduced and 9 closed positions. Its largest new stake was Relay Therapeutics: 1,300,000 shares worth $55.4M. The largest sale was Halozyme, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2020 buy was Relay Therapeutics: 1,300,000 shares worth $55.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2020, an estimated $25.9M increase.
  • Bellevue Group's biggest Q3 2020 reduction was Halozyme, cutting an estimated $35.1M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q3 2020, selling an estimated $9.48M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.24B portfolio in Q3 2020.
  • Bellevue Group opened 18 new positions and closed 9 in Q3 2020.
  • Bellevue Group's portfolio value rose 2.4% quarter-over-quarter to $7.24B.

Based on Bellevue Group's 13F filing for Q3 2020, filed 16 Nov 2020.